Peptide therapy in the US: the FDA reclassification explained
The FDA reclassified several peptides in 2025-2026, moving compounds between compounding categories, and the clinic market reorganized around what remained legal. The honest state:
What happened
The FDA's 503A/503B bulks-list process moved 14 peptides from restricted back to Category 1 (legal for compounding) - covered by AJMC as the "peptide reversal". Compounding pharmacies resumed supply; peptide menus reappeared at longevity and men's-health clinics nationwide.
What clinics actually sell now
- BPC-157 / TB-500 injectables marketed for repair.
- CJC-1295 / ipamorelin growth-hormone secretagogues marketed for sleep, recovery, body composition.
- Sermorelin the longest-standing secretagogue (see the sermorelin treatment page).
- GLP-1s (semaglutide, tirzepatide) the "peptide" most men actually receive, at published tiers like TRT Nation's $219/mo.
The evidence honesty check
Human-trial evidence in healthy men is thin for nearly all compounds; marketing extrapolates animal and injury-model studies. GH secretagogues require IGF-1 monitoring because over-stimulation carries metabolic and cancer-risk questions. A clinic selling peptides without baseline labs and a monitoring schedule fails the same checklist logic as any other provider.
Pricing
$200-800 per month per compound is the clinic band reported in trade press, with men in their 40s cited as the demand driver. GLP-1s are their own economy. Nobody should stack peptides on TRT before TRT itself is stable and monitored.
Sources: AJMC; trade press; provider pages fetched 2026-10-08. Not medical advice.
Frequently asked questions
Are peptides like BPC-157 legal in the US?
How much does peptide therapy cost at a clinic?
Information directory — publicly available pricing compared, not medical advice · Source-checked 2026-10-09 · Independent directory — not medical advice.